TrialIntensive care medicine2018

Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study).

Tobias Welte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.